Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

Autor: Capoluongo ED, B, Pellegrino, Arenare L, Califano D, Scambia G, L, Beltrame, V, Serra, Scaglione GL, Spina A, Cecere SC, De Cecio R, N, Normanno, N, Colombo, Lorusso D, Russo D, Nardelli C, M, D'Incalci, Llop-Guevara A, Pisano C, G, Baldassarre, Mezzanzanica D, Artioli G, Setaro M, Tasca G, C, Roma, Campanini N, Cinieri S, A, Sergi, Musolino A, Perrone F, Chiodini P, S, Marchini, Pignata S

Publikováno v: Scientia

Molecular testing; Ovarian cancer Proves moleculars; Càncer d'ovaris Pruebas moleculares; Cáncer de ovarios Background The detection of homologous recombination deficiency (HRD) can identify patients who are more responsive to platinum and poly ADP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdf39ab4ed238d4e922aed12d4c930dd
https://hdl.handle.net/11351/8362

Identification and Characterization of a New BRCA2 Rearrangement in an Italian Family with Hereditary Breast and Ovarian Cancer Syndrome

Autor: Evelin Schröck, Roberta Rizza, Ettore Capoluongo, Paola Concolino, Cecilia Zuppi, Angelo Minucci, Giovanni Luca Scaglione, Alessandra Costella, Maria De Bonis, Karl Hackmann

Publikováno v: Molecular diagnosistherapy. 21(5)

Introduction Many studies document the involvement of BRCA1/2 gene rearrangements in genetic predisposition to breast and ovarian cancer. Large genomic rearrangements (LGRs) of BRCA1 account for 0-27% of all disease-causing mutations in various popul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db1669556aa1b7f04f92e82fafeec08
https://pubmed.ncbi.nlm.nih.gov/28620890

A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations

Autor: Paola Concolino, Ettore Capoluongo, Cecilia Zuppi, Giovanni Scambia, Alessandra Costella, Concetta Santonocito, Vanda Salutari, Giovanni Luca Scaglione, Angelo Minucci

Background Recent advances in next generation sequencing (NGS) technology have enabled comprehensive and accurate screening of the entire genomic region of BRCA1 / 2 genes and, to date, many studies report the effectiveness of these technologies. Her

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3147cae480f669a381f9b846f952e94a
http://hdl.handle.net/11588/777964

Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa.

Autor: Primerano A; Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy., De Domenico E; Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy., Cianfarani F; Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy., De Luca N; Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy., Floriddia G; Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy., Teson M; Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy., Cristofoletti C; Laboratory of Molecular Oncology, IDI-IRCCS, Rome, Italy., Cardarelli S; Laboratory of Experimental Medicine, Department of Surgery, Sapienza University, Rome, Italy., Scaglione GL; Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy., Baldini E; Laboratory of Experimental Medicine, Department of Surgery, Sapienza University, Rome, Italy., Cangelosi D; Clinical Bioinformatics, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Uva P; Clinical Bioinformatics, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Reinoso Sánchez JF; Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy., Roubaty C; Department of Biology, University of Fribourg, Fribourg, Switzerland., Dengjel J; Department of Biology, University of Fribourg, Fribourg, Switzerland., Nyström A; Department of Dermatology, University of Freiburg, Freiburg, Germany., Mastroeni S; Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy., Ulisse S; Laboratory of Experimental Medicine, Department of Surgery, Sapienza University, Rome, Italy., Castiglia D; Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy., Odorisio T; Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy.

Publikováno v: The British journal of dermatology [Br J Dermatol] 2024 Sep 18; Vol. 191 (4), pp. 568-579.

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.

Autor: Pignata S; Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples. Electronic address: s.pignata@istitutotumori.na.it., Califano D; Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples., Lorusso D; Gynecologic Oncology Unit, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome; Catholic University of Sacred Heart, Rome., Arenare L; Clinical Trial Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples., Bartoletti M; Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano., De Giorgi U; Dipartimento Oncologico, IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST Dino Amadori), Meldola., Andreetta C; Dipartimento di Oncologia, ASU FC S. Maria della Misericordia-Udine, Meldola., Pisano C; Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples., Scambia G; Gynecologic Oncology Unit, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome; Catholic University of Sacred Heart, Rome., Lombardi D; Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano., Farolfi A; Clinical and Experimental Oncology Unit, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, IRCCS, Meldola., Cinieri S; U.O.C. Oncologia Medica-Ospedale Senatore Antonio Perrino, Brindisi., Passarelli A; Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples., Salutari V; Gynecologic Oncology Unit, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome., De Angelis C; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples., Mignogna C; Division of Anatomic Pathology and Cytopathology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples., Priolo D; Oncology Unit, S Vincenzo Hospital, Taormina., Capoluongo ED; Department of Molecular Medicine and Medical Biotechnology, Università degli Studi di Napoli Federico II, Naples; Azienda Ospedaliera per L'Emergenza, Catania., Tamberi S; Oncology Unit, Santa Maria Hospital, Ravenna AUSL Romagna, Ravenna., Scaglione GL; Istituto Dermopatico Dell'Immacolata IDI-IRCSS, Rome., Arcangeli V; UO Oncologia-Ospedale degli Infermi Rimini, Rimini., De Cecio R; Division of Anatomic Pathology and Cytopathology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples., Scognamiglio G; Division of Anatomic Pathology and Cytopathology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples., Greco F; Medical Oncology Unit, AULSS 9 Regione Veneto, Scaligera-Ospedale Generale Mater Salutis, Legnago., Spina A; Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples., Turinetto M; Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin., Russo D; Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples., Carbone V; Gynecologic Oncology Unit, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome., Casartelli C; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Schettino C; Clinical Trial Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples., Perrone F; Clinical Trial Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Jul; Vol. 35 (7), pp. 667-676. Date of Electronic Publication: 2024 May 03.